Dr. Perry was appointed as CEO on 2 June 2017, after serving on the Board since 6 February 2013. From 2014 – 2017, Dr. Perry served as Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit. and from 2012 – 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a US affiliate of Switzerland-based Novartis AG. Dr. Perry, based in the United States, has previously served as the Global Head of R&D at Baxter Healthcare, President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, LLC based in San Francisco California. During the past three years Dr. Perry has also served as a Director of the following other listed companies:
Arrowhead Pharmaceuticals * (Appointed December 2011)
* denotes current directorship
Mr Rooney has more then 20 years experience in senior finance and operations management, in both pharmaceutical wholesale distribution, and medical devices. Tim joined Avita Medical as CFO in 2012 and has also served the company as the Interim CEO from late 2013 to early 2015. Previously Mr. Rooney was an owner of PDI Enterprises, Inc., a pharmaceutical wholesale distributor, where he served as the CFO/COO. Mr. Rooney spearheaded and managed the growth of PDI from an early-stage regional operator to a market-leading company with national stage presence growing revenues from $5m to $430m. Mr. Rooney holds degrees in Finance and Economics.
Senior VP Clinical Development
Mr Quick has 21 years experience in the medical device sector, and has particular expertise in design, development and clinical research. Prior to joining Avita in 2010, Andy headed US clinical research for investigational devices and post-market research for Advanced Bionics, LLC. Prior to that, Mr. Quick spent 10 years as VP of SonaMed Corporation, developing hearing screening and diagnostic devices. At Avita, Andy has implemented all aspects of its clinical strategy in several territories, and managed the FDA approval trial in burns. Mr. Quick holds degrees in Biomedical Engineering.
VP Global Operations
Mr Fencil has 30 years medical device experience, in biomaterials, device design and development, operations, and quality systems. David worked for 14 years at the Alfred Mann Foundation, a technology incubator in Valencia, CA, and related companies, where he managed development projects, quality system revisions and operational departments. David came to Avita Medical in a product development role in 2012, and has managed the development of ReCell® into the two further presentations: ReGenerCell™ and ReNovaCell™. Mr. Fencil holds degrees in Polymer Science and Business Administration.